What is KPTI stock price today?

KPTI (Karyopharm Therapeutics Inc) stock is trading at $8.28 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is KPTI stock going up or down today?

KPTI stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy KPTI stock now?

The decision to buy KPTI depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is KPTI a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for KPTI based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is KPTI stock overvalued or undervalued?

Use our DCF valuation calculator to determine if KPTI is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is KPTI's P/E ratio?

P/E ratio data for KPTI will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is KPTI's market cap?

KPTI (Karyopharm Therapeutics Inc) has a market capitalization of $0.19 billion, making it a small-cap stock.

What is KPTI's price to book ratio?

KPTI trades at a price-to-book (P/B) ratio of 12.05, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does KPTI pay dividends?

KPTI does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is KPTI's dividend yield?

KPTI does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is KPTI stock a good long-term investment?

KPTI's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is KPTI's revenue growth rate?

KPTI has shown revenue growth of 0.1% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

KPTI is currently operating at a loss. Some companies prioritize growth over profitability in early stages. Review our financial analysis for detailed insights.

What are the risks of investing in KPTI?

Key risks for KPTI include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does KPTI compare to its competitors?

Compare KPTI to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize KPTI's performance and positioning.

What is KPTI's stock price target for 2026?

Our AI model provides price targets for KPTI based on fundamental analysis: Bull case $10.76 (+30%), Base case $9.52 (+15%), Bear case $7.45 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about KPTI?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for KPTI. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is KPTI's next earnings report?

KPTI reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

KPTI - Karyopharm Therapeutics Inc

NYSE * Health Care * Biotechnology

$8.28

+$0.28 (+3.50%)

About Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

KPTI Key Statistics

Market Cap

$186.66M

P/B Ratio

12.05

EPS

$-17.93

Revenue Growth

+0.1%

Profit Margin

-1.3%

Employees

228

How KPTI Compares to Peers

KPTI has the fastest revenue growth among competitors

KPTI is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
KPTI(This stock)	$186.66M	N/A	0%	-1.3%	-
AMGNAmgen Inc	$188.58B	24.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$172.56B	20.5	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$111.93B	28.7	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$78.92B	18.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$25.88B	20.1	-0%	0.1%	vs BIIB

Karyopharm Therapeutics Inc Company Information

Headquarters: Massachusetts; U.S.A
Website: www.karyopharm.com
Sector: Health Care
Industry: Biotechnology

KPTI - Karyopharm Therapeutics Inc

About Karyopharm Therapeutics Inc

KPTI Key Statistics

How KPTI Compares to Peers

Karyopharm Therapeutics Inc Company Information

KPTI Lician Score

KPTI Financial Snowflake

Upcoming Events for KPTI